Aneel K Aggarwal, PhD
- PROFESSOR | Pharmacological Sciences
- PROFESSOR | Oncological Sciences
Research Topics:
DNA Repair, DNA Replication, Structural Biology, Transcription Factors, Translation
Dr. Aggarwal is an internationally recognized structural biologist, who earned his PhD in biophysics at Kings College, University of London, in 1984. From 1985 to 1987, Dr. Aggarwal participated in a NATO research fellowship and was also a postdoctoral fellow in the Department of Biochemistry and Molecular Biology at Harvard University. He then became an Assistant Professor at Columbia University before joining the Mount Sinai Medical School. He is currently a Professor in the Department of Structural & Chemical Biology and holds an Endowed Chair as the Mount Sinai Professor in Structural Biology.
Dr. Aggarwal is a member of the Cancer Mechanisms Program at The Tisch Cancer Institute.
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Genetics and Genomic Sciences [GGS], Pharmacology and Therapeutics Discovery [PTD]Education
PhD, Kings College, University of London
Harvard University
-
2012
Dean’s Award for Excellence in Basic Science Research -
2010
Faculty Council Award for Academic Excellence -
2007
Mount Sinai Professor in Structural Biology (Endowed Chair) -
1995
The Doctor Harold and Golden Lamport Award for Excellence in Basic Science Research -
1990
Irma T. Hirschl Career Scientist Award -
1990
Basil O'Connor Starter Scholar Research Award -
1985
The North Atlantic Treaty Organization (NATO) Research Fellowship -
1985
EMBO Long-term Fellowship (Declined) -
1981
Science and Engineering Research Council (SERC) of Great Britain Studentship
Protein-nucleic acid interactions
We use a variety of structural tools to uncover how enzymes, and transcription and translation regulators interact with nucleic acids to affect cellular development and disease outcome. We study how such proteins locate, bind, and move on their DNA or RNA sites, and, then use that knowledge to create enzymes with new specificities and obtain a molecular understanding for how genes are regulated. We are also interested in learning how cells cope with the effects of DNA damage. In particular, we investigate how a set of specialized DNA polymerases can bypass DNA damage during replication and how mutations in them can lead to cancer.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Aggarwal during 2021 and/or 2022. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Onconova Therapeutics, Inc.
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- Celgene Corporation; New England Biolabs, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.